Last Updated: October 17, 2026

Details for Patent: 8,334,279

Name: Drug Patent Intelligence for US Patent 8334279
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,334,279 protect, and when does it expire?

Patent 8,334,279 protects AGAMREE and is included in one NDA.

This patent has fifty-two patent family members in twenty-five countries.

Summary for Patent: 8,334,279

Title:	Non-hormonal steroid modulators of NF-κB for treatment of disease
Abstract:	The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
Inventor(s):	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
Assignee:	Validus Genetics , Reveragen Biopharma Inc
Application Number:	US13/327,628
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,334,279

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Catalyst Pharms	AGAMREE	vamorolone	SUSPENSION;ORAL	215239-001	Oct 26, 2023		RX	Yes	Yes	8,334,279	⤷ Start Trial				TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,334,279

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2805720	⤷ Start Trial	301273	Netherlands	⤷ Start Trial
European Patent Office	2805720	⤷ Start Trial	CA 2024 00018	Denmark	⤷ Start Trial
European Patent Office	2805720	⤷ Start Trial	PA2024518	Lithuania	⤷ Start Trial
European Patent Office	2805720	⤷ Start Trial	LUC00349	Luxembourg	⤷ Start Trial
European Patent Office	2805720	⤷ Start Trial	2024C/521	Belgium	⤷ Start Trial
European Patent Office	2805720	⤷ Start Trial	21/2024	Austria	⤷ Start Trial
European Patent Office	2805720	⤷ Start Trial	CR 2024 00018	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.